![]() “I am proud of how our company performed in 2021, helping more patients across our therapeutic areas, while achieving 9% revenue and 17% non-GAAP EPS growth, respectively,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. Provides GAAP and More Detailed Non-GAAP Financial Guidance for 2022īristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’s pipeline that further progressed the company’s portfolio renewal.Announces $15 Billion Share Repurchase Authorization $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022.Advances Pipeline with Achievement of Significant Clinical and Regulatory Milestones Builds Strong Foundation for Portfolio Renewal.Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios.Posts Fourth Quarter Earnings Per Share of $1.07 and Non-GAAP EPS of $1.83 Posts Full-Year Earnings Per Share of $3.12 and Non-GAAP EPS of $7.51.Reports Fourth Quarter Revenues of $12.0 Billion Full-Year Revenues of $46.4 Billion.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |